ArticleEClinicalMedicine2022
Neurodevelopmental and growth outcomes after invasive Group B
Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06833957 (PReparing for OptimalPhase III/IV maTErnal Group B StreptococCal Vaccine Trials in Africa), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PReparing for OptimalPhase III/IV maTErnal Group B StreptococCal Vaccine Trials in Africa (PROTECT)
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Impact of neonatal sepsis on neurocognitive outcomes: a systematic review and meta-analysis.BMC pediatrics · 2024Pooled it
- Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden.The Lancet. Global health · 2022Pooled it
- Article
- Maternal Group BClinical epidemiology · 2026Article
- The Impact of Neonatal Sepsis on Long-Term Neurodevelopment: A Systematic Review of Cognitive and Sensory Outcomes.Cureus · 2025Review
- Group BLancet regional health. Americas · 2025Article
- Risk of Depression and Anxiety in Those Who Gave Birth to Children Who Developed InvasiveClinical epidemiology · 2025Article
- Neurodevelopmental impairment associated with neonatal invasive group BBrain, behavior, & immunity - health · 2024Article
- Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis.Scientific reports · 2024Article
- Long-term healthcare utilisation, costs and quality of life after invasive group BBMJ global health · 2024Article
- Inferring longitudinal patterns of group B Streptococcus colonization during pregnancy.iScience · 2023Article
- Long-term Risk of Epilepsy Following Invasive Group B Streptococcus Disease in Neonates in Denmark.JAMA network open · 2023Article
- Maternal immunisation against Group B Streptococcus: A global analysis of health impact and cost-effectiveness.PLoS medicine · 2023Article
- Early-onset group B streptococcal disease in African countries and maternal vaccination strategies.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease. Methods: A multi-country matched cohort study was undertaken in South Africa, India, Mozambique, Kenya, and Argentina from October 2019 to April 2021. The exposure of interest was defined as a history of iGBS disease (sepsis or meningitis) before 90 days of age, amongst children now aged 1·5-18 years. Age and sex-matched, children without history of GBS were also recruited. Age-appropriate, culturally-adapted assessments were used to define NDI across multiple domains (cognitive, motor, hearing, vision, emotional-behaviour, growth). Pooled NDI risk was meta-analysed across sites. Association of iGBS exposure and NDI outcome was estimated using modified Poisson regression with robust variance estimator. Findings: Amongst 138 iGBS survivors and 390 non-iGBS children, 38·1% (95% confidence interval [CI]: 30·0% - 46·6%) of iGBS children had any NDI, compared to 21·7% (95% CI: 17·7% - 26·0%) of non- iGBS children, with notable between-site heterogeneity. Risk of moderate/severe NDI was 15·0% (95% CI: 3·4% - 30·8%) among GBS-meningitis, 5·6% (95% CI: 1·5% - 13·7%) for GBS-sepsis survivors. The adjusted risk ratio (aRR) for moderate/severe NDI among iGBS survivors was 1.27 (95% CI: 0.65, 2.45), when compared to non-GBS children. Mild impairment was more frequent in iGBS (27.6% (95% CI: 20.3 - 35.5%)) compared to non-GBS children (12.9% (95% CI: 9.7% - 16.4%)). The risk of emotional-behavioural problems was similar irrespective of iGBS exposure (aRR=0.98 (95% CI: 0.55, 1.77)). Interpretation: Our findings suggest that iGBS disease is on average associated with a higher risk of moderate/severe NDI, however substantial variation in risk was observed between sites and data are consistent with a wide range of values. Our study underlines the importance of long-term follow-up for at-risk neonates and more feasible, standardised assessments to facilitate diagnosis in research and clinical practice. Funding: This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.